View Older Stories View More Recent Stories
-
Bernstein Reiterates Market Perform Rating on Merck (MRK)
-
Merck (MRK) PT Raised to $120 at TD Cowen
-
Merck (MRK) PT Raised to $124 at Leerink Partners
-
Moderna and Merck report sustained melanoma treatment benefits at 5 years
-
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
Merck (MRK) Reiterated at Buy by UBS: Bags FDA CNPV Voucher for Sac-TMT
-
Wells lists 14 high-conviction long ideas for Q1 2026
-
STAT reported Feuerstein: meeting with Revolution Medicines CEO cancelled
-
Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ
-
Revolution Medicines (RVMD) CEO Said to Cancel Upcoming Meetings Amid M&A Chatter
-
After-hours movers: Rocket Companies, General Motors, Intel, and more
-
Merck Discussed $28B-$32B Price For Revolution Medicines - FT
-
Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
-
Merck (MRK) call put ratio 3.1 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe
-
Wolfe Research Upgrades Merck (MRK) to Outperform
-
Allegro MicroSystems, Inc. (ALGM) Wells Fargo 14 High-Conviction 2026 Ideas
-
BofA unveils its top 10 U.S. ideas for Q1 2026
-
BofA: 'our Top 10 Ideas include nine Buys and one Underperform across nine industries'
-
FDA awards priority vouchers to two investigational drugs
-
Merck agrees with US government to expand medicine access and cut costs
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Trump to announce prescription drug price agreements
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
FDA to fast-track reviews of two Merck drugs under commissioner national priority voucher pilot program - Reuters
-
Merck reports positive results for KEYTRUDA plus Padcev in bladder cancer
-
Merck gets EU committee backing for expanded WINREVAIR use in PAH
-
FDA launches fresh safety scrutiny of approved RSV therapies for infants - Reuters
-
Merck (MRK) PT Raised to $122 at Guggenheim
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
FDA conditionally approves Merck's cattle parasite treatment product
-
Top drug regulator Richard Pazdur set to leave FDA - Stat
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Merck receives FDA fast track for Alzheimer's drug MK-2214
-
Merck (MRK) call put ratio 2.5 calls to 1 put as share price up 3.6%
-
MERCK to present hematology pipeline data at ASH 2025 meeting
-
Wells Fargo Upgrades Merck (MRK) to Overweight
-
FDA approves Padcev plus Keytruda for certain patients with bladder cancer
-
FDA approves Keytruda and Padcev combo for bladder cancer treatment
-
European Commission approves subcutaneous KEYTRUDA for all adult indications
-
Merck (MRK) Declares $0.85 Quarterly Dividend; 3.5% Yield
-
Merck to acquire Cidara for $9.2 billion to gain influenza drug
-
Merck (MRK) call put ratio 4.6 call1 to 1 put
-
Merck (MRK) Nearing Deal To Buy Cidara Therapeutics- FT
-
Analysts cautious following Merck’s CMD, Morgan Stanley flags near-term risks
-
Merck (MRK) PT Raised to $114 at Leerink Partners
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
